R Matthew Walsh
Cleveland Clinic
Appearances
- DateMay 9, 2023Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
Presenter
Speakers
Cleveland ClinicCleveland Clinic - DateMay 9, 2023SOCIETY: DDW
Moderators
Cleveland ClinicJawaharlal Institute of Postgraduate Medical Education and ResearchHospital of the University of PennsylvaniaThe University of Texas MD Anderson Cancer Center - DateMay 9, 2023SOCIETY: DDW
Presenter
Cleveland Clinic - DateMay 9, 2023BACKGROUND: To address the persistent ethnoracial and socioeconomic disparities in access to quality surgical cancer care, it is imperative to rigorously understand the role of clinician-level factors including clinician-to-clinician connectedness…
Presenter
Speakers
- DateMay 6, 2023We present the case of a 67-year-old woman who had two IPMN in the pancreas body (4 and 2 cm) and underwent robotic distal pancreatectomy with spleen preservation…
Presenter
Speakers
Cleveland Clinic - DateMay 6, 2023LUNCH AND TRAINEE JEOPARDY! 12:00 PM - 1:00 PM LEADERSHIP FORUM, NETWORKING SESSION AND ROUNDTABLES 4:00 PM - 5:30 PM KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY 4:00 PM - 4:30 PM
Presenter
Speakers
- DateMay 18, 2024RISK FACTORS FOR REGROWTH AFTER NONOPERATIVE MANAGEMENT FOR RECTAL CANCER
Moderators
Stony Brook University HospitalCleveland ClinicUniversity of Wisconsin-MadisonUniversity of Alabama at Birmingham (UAB)Speakers
Massachusetts General Hospital - DateMay 20, 2024Minimally invasive pancreaticoduodenectomy (MIPD), or the Whipple procedure, is increasingly utilized. No study has compared laparoscopic (LPD) and robotic (RPD) approaches, and the impact of the learning curve on oncologic, technical, and post-operative outcomes remains relatively understudied…
Presenter
Speakers
- DateMay 21, 2024Intrahepatic Cholangiocarcinoma (iCCA) is rare but deadly. Neoadjuvant systemic therapy (NAST) is frequently employed, though its’ impact on short-term oncologic outcomes and/or survival remains relatively unknown…
Presenter
Speakers
Cleveland ClinicCleveland ClinicCleveland Clinic - DateMay 4, 2025SOCIETY: SSAT
Moderators